We are diligently and sustainably achieving
excellence in all that we do



Aurobindo Pharma Ltd. is a vertically integrated pharmaceutical company that delivers innovative solutions. From discovery to development to commercialization, our growth is aided by cost-effective drug development and substantial manufacturing.

Leveraging India’s globally competitive cost base and talented team of scientists, we have successfully launched a range of affordable products which are accessible across the globe.


We have 15 state-of-the-art formulation manufacturing facilities located in India, USA, Portugal and Brazil. Our facilities have received accreditations from the following regulatory bodies:

  • US FDA (United States Food and Drug Administration)
  • UK’s MHRA (United Kingdom’s Medicines and Health products Regulatory Agency)
  • TGA Australia (Therapeutic Goods Administration)
  • MCC South Africa (Medicines Control Council)
  • ANVISA Brazil (National Health Surveillance Agency)
  • Health Canada
  • WHO (World Health Organization)
  • GCC DR (Gulf Central Committee for Drug Registration)

Business Models

Aurobindo has a sustainable network of alliances and partnerships across the globe. The company has carved a niche for itself in the global regulated market.

We Aspire to:

  • Grow through territory expansions, partnerships, globalization & further penetration through joint ventures and subsidiaries in attractive markets.
  • Develop a broad portfolio of products through non-infringing processes and become a significant player in the generics arena.
  • Emerge as a leading global player in high quality, innovative specialty generic formulations.

Manufacturing Capabilities

Aurobindo has retained the same drive for growth that marked its early days. Starting with a small SSP manufacturing unit in 1988, Aurobindo has grown to become the market leader in SSPs, non penicillins, cephalosporins, and non cephalosporins. In the global market, we believe in retaining our leadership in SSPs, cephalosporins, new anti-infectives and lifestyle disease drugs.

Our Core Strengths

  • Vertically integrated operations from conception to commercialization.
  • Large manufacturing capabilities for a diversified product portfolio.
  • Efficient regulatory affairs team ensuring market compliance.
  • Dedicated R&D setup for finished dosages and active ingredients.
  • Technology and expertise for specialty formulations

Our Key Formulation Facilities (8 in India, 1 each in US and Brazil)

Unit 3

  • An exclusive multi-product oral dosage form facility spread over 40,469 sq. meters for non cephalosporins and non-beta-lactams

Unit 4

  • A dedicated manufacturing facility for generic sterile injectable (lyophilized and powder injections, prefilled syringes), ophthalmic and low volume parenteral.
  • The facility is spread over 33 acres with a built-up area of 20,000 square meters.

Unit 7

  • An ultra-modern unit based on the suite manufacturing concept delivering huge capacity.
  • Manufactures non penicillins, non cephalosporins & ARVs

Unit 10

  • Manufactures non penicillins & non cephalosporins products .

Unit 12

  • A dedicated facility spread over 15,228 square meters, manufacturing oral and sterile beta-lactam formulations..

Unit 15

  • An exclusive multi-product oral dosage form facility spread over 1,000,000 square meters, built in a 23 acre campus for supplying European markets.
  • Unit has an installed annual capacity of 6 billion tablets and capsules.


  • Produces sterile penne formulations.
  • Also manufactures sterile APIs.

Aurolife (Located in the US)

  • A 100,000 square feet state-of-the-art USFDA approved CGMP compliant manufacturing facility located in New Jersey
  • Manufactures non-penicillin’s and non-cephalosporin products


  • Have an exclusive manufacturing facility for SSPs, which caters to the requirements of Latin America

Our Range of Formulations

Geographical Presence

Aurobindo Pharma is well-known as a global supplier of generic Antiretroviral (ARV) drugs because of its strong customer centricity. Our products are updated continuously to suit the changing needs of our customers. We market more than 300 products in various therapeutic segments over 150 countries. We are building and establishing our brands as we develop significant strength in our chosen markets. We also have strategic alliances with global pharmaceutical majors to cater to their formulation manufacturing needs.